Sunlenca 300MG tab, PKT,5
Ended Awarded Last action
- Contract number
- 36C26025F0137
- Awardee
-
Gilead Sciences Inc. UEI FPJMGUK1BYH8
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $3,103
Award facts
- Contract value 100% obligated
- $3,103.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Dublin, OH 43017, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$779 | |
| Original award | $3,882 |
About this award
Gilead Sciences Inc. has been awarded a delivery order by Veterans Integrated Service Network 20 (VISN 20), a civilian component of the Department of Veterans Affairs, for Sunlenca 300mg tablets in a quantity of five packets. The contract, awarded on January 28, 2025, carries a firm fixed price ceiling value of $3,103.02 with an ultimate completion date of February 18, 2025. This delivery order was issued without a small business set-aside designation and will be performed in Dublin, Ohio. The award falls under Gilead's parent General Services Administration Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), through which the company supplies specialized pharmaceutical products to VA facilities nationwide.
This contract represents a routine pharmaceutical procurement within Gilead's ongoing relationship with the VA, which includes a significant $29.16 million blanket purchase agreement valued through October 31, 2025, and a $33 million multiple-award Federal Supply Schedule contract. Sunlenca (lenacapavir) is an HIV treatment medication that addresses critical healthcare needs for veterans, consistent with Gilead's established role as a primary supplier of advanced antiretroviral and therapeutic medications to federal healthcare programs. The modest contract value reflects the specific quantity and type of pharmaceutical supply being delivered through this individual delivery order against the larger GSA Schedule vehicle.
Quick answers
Who was awarded contract 36C26025F0137?
36C26025F0137 was awarded to Gilead Sciences Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on January 28, 2025.
How much is contract 36C26025F0137 worth?
The government has obligated $3,103 on 36C26025F0137.
Is contract 36C26025F0137 an order under another contract?
Yes. 36C26025F0137 is a delivery order under V797D70252, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0137 competed?
The extent of competition for 36C26025F0137 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award